Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029, Highlighting Recurrent and Metastatic Innovations
"Metastatic Cancer: A Significant Therapeutic Challenge as Pharmaceutical Companies Leverage Digital Platforms and Data to Enhance Engagement with Patients, Providers, and Regulators in the Growing Cancer Therapeutics Market"
BOSTON, June 30, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions" is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029 at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.
This report provides a comprehensive analysis of the global market for cancer therapeutics. It covers the history, forms, pathophysiology, stages, and mechanisms of cancer metastasis and recurrence. The report also examines the disease burden through cancer epidemiology. It discusses various treatment patterns, including non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, chemotherapy, combinatorial therapy) approaches.
Additionally, it analyzes the most frequently used products, clinical trials, new product approvals, and the growth prospects of the regions of North America, Europe, Asia-Pacific, and the Rest of the World. Profiles of leading companies and their strategies in the cancer treatment sector are also included.
This report is particularly relevant today due to the urgent need for new treatments for metastatic cancers, which are responsible for about 90% of cancer-related deaths. The aggressive nature of metastatic disease and the challenge of overcoming resistance to existing therapies highlight the importance of this market. The rapid evolution of combination therapies which integrate immunotherapy, targeted therapy, and chemotherapy, offers promising advances in increasing treatment efficacy and overcoming resistance, making this a critical area of focus.
The factors driving the market's growth include:
Approval of Oncology Drugs: Faster approval processes, like the FDA's accelerated pathway, help new cancer drugs reach patients sooner, encouraging innovation.
Technological Advances: Innovations such as personalized medicine, AI in treatment planning, and immunotherapy make cancer treatments more effective.
Increasing Cancer Incidence: The rise in the number of cancer cases due to aging populations and lifestyle changes drive the demand for new treatments.
Promising Late-Stage Drugs: Many new drugs in late-stage trials show potential for better efficacy and fewer side effects, offering hope for improved cancer care.
Request a sample copy of the report on the global market for cancer therapeutics emphasizing recurrent and metastatic divisions.
Report Synopsis
Report Metric
Details
Base year considered
2023
Forecast period considered
2024-2029
Base year market size
$108.1 billion
Market size forecast
$168.0 billion
Growth rate
CAGR of 7.7% from 2024 to 2029
Segments covered
By Cancer Type and Region
Regions covered
North America, Europe, Asia-Pacific, and the Rest of the
World (RoW)
Countries covered
The U.S., Canada, Mexico, Germany, U.K., Italy, France,
Spain, Japan, China, India and South Korea
Market drivers
• Approval of oncology drugs.
• Technological advances in cancer treatments.
• Increasing incidence of cancer.
• Promising drugs in the late stage of the pipeline.
Interesting facts:
Common metastatic cancers include breast, lung, prostate, colorectal cancer, and melanoma.
According to the National Cancer Institute, about 30% of women with early-stage breast cancer may eventually develop Stage 4 (metastatic) breast cancer.
In 2024, Takeda's fruquintinib (FRUZAQLA) was approved by the European Commission for treating metastatic colorectal cancer in adults.
In 2024, the US FDA approved Bristol Myers Squibb's Opdivo, combined with Cisplatin and Gemcitabine, for treating unresectable or metastatic urothelial carcinoma in adults.
Emerging startups:
Oricell Therapeutics: Clinical-stage biotech company that develops effective and affordable cell therapies for the global patient community. Oricell's pipeline includes drugs for liquid as well as solid tumors.
Cybrexa: Platform technology company that makes it possible for small-molecule anti-cancer medications to target tumors and metastases without antigens and to penetrate deep tissue. The company's goal is to help cancer patients live more satisfying lives by providing them with new treatment options.
Asher Biotherapeutics Inc.: Cis-targeted immunotherapies are a novel approach pioneered by Asher. Its immunotherapies activate only the specific immune cell types that support the intended therapeutic response. The indiscriminate action of conventional immunotherapies on various cell types, which leads to suboptimal efficacy and adverse effects, will be addressed by this novel approach.
The report addresses the following questions:
What is the projected market size and growth rate?• The global market for cancer therapeutics emphasizing recurrent and metastatic divisions was valued at $108.1 billion in 2023 and is projected to reach $168.0 billion by the end of 2029.
What factors are driving the growth of the market?• The increasing incidence of cancer, approvals of oncology drugs, and technological advances in cancer treatments are driving the market's growth.
Which market segments are covered in the report?• This report segments the market scope into cancer types. The report covers lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, cervix cancer, bladder cancer, kidney cancer, pancreas cancer, ovary cancer, and other cancers.
Which cancer type segment will be dominant through 2029?• Lung cancer will dominate the cancer therapeutics market with an emphasis on recurrent and metastatic divisions.
Which region has the largest market share?• The North American market was valued at $48.1 billion in 2023 and is projected to reach $75.3 billion in by the end of 2029, at a CAGR of 7.8% during the forecast period.
Market leaders include:
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
Related reports:
Artificial Intelligence (AI) in Cancer: The report on AI technology in cancer applications outlines the market's current and future potential, analyzing drivers, restraints, and opportunities. It projects market trends through 2029, segmented by application (screening, diagnosis, therapy, drug discovery), cancer type (breast, lung, prostate, etc.), and end user (hospitals, diagnostic centers). The report also analyzes the market in the regions of North America, Europe, Asia-Pacific, and the Rest of the World, with profiles of major companies and their recent developments.
Global Oncology Pharmaceuticals Market: The report provides a comprehensive analysis of the global oncology pharmaceuticals market, covering drug types like targeted therapy, immunotherapy, chemotherapy, and hormone therapy. It examines market revenues by cancer type, including lung, breast and prostate. The report also analyzes regional market revenues for North America, Europe, Asia-Pacific, and the Rest of the World. Additionally, it includes profiles of leading companies, a discussion of the competitive landscape, pipeline and patent analysis, and a discussion of market drivers and restraints.
Purchase a copy of the report direct from BCC Research.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Contact UsCorporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@bccresearch.comPhone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/cancer-therapeutics-market-forecast-to-reach-168-billion-by-2029-highlighting-recurrent-and-metastatic-innovations-302494859.html
SOURCE BCC Research LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
22 minutes ago
- CNN
‘Musk is right about this': Elizabeth Warren shocked to find agreement with Musk over megabill
CNN's Kaitlan Collins talks with Sen. Elizabeth Warren (D-MA) about finding surprising common cause with Elon Musk over their shared objections to President Trump's megabill.
Yahoo
22 minutes ago
- Yahoo
Mark Zuckerberg overhauled Meta's entire AI org in a risky, multi-billion dollar bet on ‘superintelligence'
Mark Zuckerberg is stacking the deck in the AI race, betting that unlimited capital, top talent, and raw computing power will ensure victory. If the winning hand Zuckerberg is chasing—AI 'superintelligence'— is still very much a vague and theoretical concept, the Meta CEO's remarkable series of moves unveiled Monday instantly changed the reality for everyone else in the game, particularly the pioneering AI startups without Meta's resources. Zuckerberg announced a major revamp of its AI operations on Monday, putting the company's collection of AI businesses and projects under the umbrella of a newly created organization called Meta Superintelligence Labs, or MSL, and appointing Alexandr Wang, the former CEO of data-labeling startup Scale AI, as Meta's first ever Chief AI Officer. 'As the pace of AI progress accelerates, developing superintelligence is coming into sight,' Zuckerberg wrote in an internal memo obtained by Fortune. 'I believe this will be the beginning of a new era for humanity, and I am fully committed to doing what it takes for Meta to lead the way.' He added that the details he would share were about building towards a company vision of 'personal superintelligence for everyone.' The new superintelligence lab, Zuckerberg wrote, 'includes all of our foundations, product, and FAIR teams, as well as a new lab focused on developing the next generation of our models.' He also confirmed that former GitHub CEO and investor Nat Friedman has also joined Meta to partner with Wang to lead MSL, heading Meta's work on AI products and applied research. 'Nat has served on our Meta Advisory Group for the last year, so he already has a good sense of our roadmap and what we need to do,' Zuckerberg wrote. Fortune reported last week that Friedman is also connected with Wang and Scale – he is a longtime and active Scale investor and co-hosted the secretive Scale AI Security Summit in Utah in November 2023. Meta has embarked on an extraordinary hiring spree in recent weeks, bringing Wang on board as part of a $14.3 billion deal with Scale, and recruiting top researchers from OpenAI with rumored $100 million compensation offers. In Zuckerberg's internal memo on Monday, he named eleven top researchers who had joined Meta from OpenAI, Anthropic and Google. For OpenAI, which kicked off the generative AI craze with the release of ChatGPT in late 2022, Meta's aggressive hiring spree represents a critical threat. OpenAI's chief research officer Mark Chen described the situation as feeling like someone 'breaking into our home,' calling the talent loss 'theft.' OpenAI said it had begun recalibrating compensation and crafting 'creative' retention packages to stay competitive. While OpenAI has a longstanding partnership with Microsoft, which has invested more than $13 billion in OpenAI, the relationship between the two companies has reportedly grown strained over the past year. As Meta increasingly seeks to move into OpenAI's territory however, the Sam Altman led startup may need to find allies with deep pockets. OpenAI recently began using AI chips made by Google, according to media reports, signaling a growing bond between the two companies, even though Google's Gemini LLMs compete directly with OpenAI. With an internet advertising business that generates more than $40 billion every quarter, Meta can afford to bankroll a no-holds-barred AI batter even it doesn't immediately deliver a profit. Still, Meta's latest moves carry plenty of risks. In making Wang chief AI officer, Meta has chosen someone who is not a computer scientist to lead all of its AI efforts—a choice that may not go over well with Meta's deep bench of AI scientists and PhDs, many of whom have already decamped. Zuckerberg noted in his memo that he and Wang had worked together for several years and said 'I consider him to be the most impressive founder of his generation.' There is also no agreed-upon formal definition of 'superintelligence,' though it is typically refers to an intelligence that vastly surpasses human capabilities in virtually all domains, including scientific creativity, general wisdom, and social skills—exceeding human cognition across the board. Superintelligence is generally perceived as going beyond artificial general intelligence, or AGI, which, though also vague, typically refers to an AI system with human-level intelligence across a wide range of work-related tasks. That is, it can reason, plan, solve problems, understand language, and learn in a generalizable way, much like a human. Zuckerberg claimed that Meta is 'uniquely positioned to deliver superintelligence to the world,' pointing to its efforts to build out data centers supporting more computing power than smaller labs – it is currently spending tens of billions on data centers and is raising more. The Financial Times reported last week that Meta is seeking $29 billion from private capital firms for its all-in push to build AI data centers. Of course, Microsoft and Google are also spending tens of billions of dollars in cap ex to build out their AI infrastructure. And OpenAI has said it intends to invest $500 billion with partners including Softbank in the coming years to build out its Stargate network of AI datacenters. If the race to Superintelligence is a test of wills and capital, Zuckerberg seems to be betting that he can outlast the competition. This story was originally featured on
New York Times
26 minutes ago
- New York Times
NBA free agency 2025 tracker, live updates: Latest deals, news, reaction and more as negotiating window opens
The Hawks' Dejounte Murray trade with New Orleans keeps on paying dividends. Not only did Atlanta obtain the pick that went to the Celtics for Kristaps Porziņģis and defensive stopper Dyson Daniels, but also the $25 million trade exception that deal generated now has been used to acquire Nickeil Alexander-Walker from the Minnesota Timberwolves. Atlanta will still have several million of that exception left over, as well as its full $14.1 million nontaxpayer midlevel exception and a $13 million exception from the Bogdan Bogdanović trade. But as a practical consequence, a hugely productive offseason in Atlanta is now down to smaller moves. Atlanta sent only a second-round pick to Minnesota in the sign-and-trade to assure it topped every other team on the market, ultimately going a shade over the nontaxpayer midlevel exception to get Alexander-Walker. The Hawks still have roughly $13 million remaining below the tax line with at least two more roster spots to fill, and seem likely to target another guard based on current needs. For its trouble, Minnesota will receive a trade exception for roughly $14.4 million. The Wolves are hugely unlikely to use it this season because they're way over the first apron, but it's a possibility for next summer.
